John P. Sharp
Net Worth
Last updated:
What is John P. Sharp net worth?
The estimated net worth of Mr. John P. Sharp is at least $3,615,291 as of 3 Nov 2021. He owns shares worth $351 as insider and has received compensation worth at least $3,614,940 in PhaseBio Pharmaceuticals, Inc..
What is the salary of John P. Sharp?
Mr. John P. Sharp salary is $516,420 per year as Chief Financial Officer in PhaseBio Pharmaceuticals, Inc..
How old is John P. Sharp?
Mr. John P. Sharp is 60 years old, born in 1965.
What stocks does John P. Sharp currently own?
As insider, Mr. John P. Sharp owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
PhaseBio Pharmaceuticals, Inc. (PHAS) | Chief Financial Officer | 5,000 | $0.07 | $351 |
What does PhaseBio Pharmaceuticals, Inc. do?
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
John P. Sharp insider trading
PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals key executives
PhaseBio Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. John S. Lee (57) Chief Medical Officer
- Mr. John P. Sharp (60) Chief Financial Officer
- Mr. Jonathan P. Mow (60) Pres, Chief Executive Officer & Director